Germany - Drugs

Description

The participating health insurance funds are pursuing the goal of concluding rebate contracts with all suitable pharmaceutical companies in accordance with Section 130a (8) of the German Social Code, Book V for the active ingredient glycopyrronium bromide (dosage form: hard capsules with powder for inhalation). The contract is concluded within the framework of the health insurance funds' open-house original procedure:Individual negotiations on contract content are not conducted; uniform conditions apply. The health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months beginning on 01.06.2023. The contract ends on 31.05.2025 at the latest, irrespective of the date on which the contract was concluded. In case of patent expiration before the above mentioned end date, the contract ends automatically with the expiration of the month of patent expiration. All further information can be found in the participation and contract documents.
It is possible to join this open house original procedure at any time during the term of the contract. Due to the existence of industrial property rights with regard to the active ingredient covered by the agreement, the participation and contract documents will only be made available to those pharmaceutical companies that offer/market drugs for the active ingredient covered by the agreement or that credibly demonstrate to TK that they intend to offer/market drugs for the active ingredient covered by the agreement within the term of the agreement.A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of approval and company) and confirm this in electronic form in accordance with Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is in any way connected with submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations.

Opportunity closing date

31 May 2025

Value of contract

to be confirmed